跳至主要内容
临床试验/NCT03248141
NCT03248141终止不适用

UNDERSTANDING HEMOPHILIA A AND B DRUG DOSAGE ADMINISTRATION PATTERNS

Pfizer3 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2017年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
发起方
Pfizer
入组人数
11
试验地点
3
主要终点
Resource Utilization Pattern

研究概览

简要总结

Study Design

A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings.

30 sites will enroll approximately 300 patients

Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate.

Physicians complete a retrospective chart review on each enrolled patient.

Patients will complete a one-time study questionnaire.

详细描述

Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. Subjects currently enrolled into the study have completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Hemophilia B

real world administration patterns and resource utilization implications

干预措施: Hemophilia B standard half-life (Drug)

Hemophilia B

real world administration patterns and resource utilization implications

干预措施: Hemophilia B extended half-life (Drug)

Hemophilia A

real world administration patterns and resource utilization implications

干预措施: Hemophilia A standard half-life (Drug)

Hemophilia A

real world administration patterns and resource utilization implications

干预措施: Hemophilia A extended half-life (Drug)

结局指标

主要结局

Resource Utilization Pattern

时间窗: From baseline up to end of study (6 months)

Dosing Pattern

时间窗: From baseline up to end of study (6 months)

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验